171 related articles for article (PubMed ID: 23835721)
1. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation.
Barcroft J; Dayoub N; Thong KJ
J Assist Reprod Genet; 2013 Nov; 30(11):1407-13. PubMed ID: 23835721
[TBL] [Abstract][Full Text] [Related]
2. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
4. [Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET].
Sun Y; Zhu YM
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 May; 38(3):305-10. PubMed ID: 19504641
[TBL] [Abstract][Full Text] [Related]
5. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.
Kol S; Lightman A; Hillensjo T; Devroey P; Fauser B; Tarlatzis B; Mannaerts B; Itskovitz-Eldor J
Hum Reprod; 1999 Sep; 14(9):2242-4. PubMed ID: 10469687
[TBL] [Abstract][Full Text] [Related]
6. Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study.
Courbiere B; Decanter C; Bringer-Deutsch S; Rives N; Mirallié S; Pech JC; De Ziegler D; Carré-Pigeon F; May-Panloup P; Sifer C; Amice V; Schweitzer T; Porcu-Buisson G; Poirot C;
Hum Reprod; 2013 Sep; 28(9):2381-8. PubMed ID: 23832792
[TBL] [Abstract][Full Text] [Related]
7. Fertility outcomes in women after controlled ovarian stimulation with gonadotropin releasing hormone agonist long protocol: fresh versus frozen embryo transfer.
Ding X; Yang J; Li L; Yang N; Lan L; Huang G; Ye H
BMC Pregnancy Childbirth; 2021 Mar; 21(1):207. PubMed ID: 33711956
[TBL] [Abstract][Full Text] [Related]
8. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
[No Abstract] [Full Text] [Related]
9. Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.
Dietrich JE; Freis A; Beedgen F; von Horn K; Holschbach V; Liebscher J; Strowitzki T; Germeyer A
Front Endocrinol (Lausanne); 2020; 11():246. PubMed ID: 32411093
[No Abstract] [Full Text] [Related]
10. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
11. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
12. Perinatal outcomes in 521 gestations after fresh and frozen cycles: a secondary outcome of a randomized controlled trial comparing GnRH antagonist versus GnRH agonist protocols.
Tomás C; Toftager M; Løssl K; Bogstad J; Prætorius L; Zedeler A; Bryndorf T; Andersen AN; Pinborg A
Reprod Biomed Online; 2019 Oct; 39(4):659-664. PubMed ID: 31409522
[TBL] [Abstract][Full Text] [Related]
13. Outcome of cryopreserved pronuclear oocytes obtained after ovarian stimulation with either HMG or recFSH and the GnRH-antagonist cetrorelix.
Asimakopoulos B; Nikolettos N; Al-Hasani S
Reprod Biomed Online; 2002; 5 Suppl 1():52-6. PubMed ID: 12537782
[TBL] [Abstract][Full Text] [Related]
14. A comparison of live birth rates and perinatal outcomes between cryopreserved oocytes and cryopreserved embryos.
Ho JR; Woo I; Louie K; Salem W; Jabara SI; Bendikson KA; Paulson RJ; Chung K
J Assist Reprod Genet; 2017 Oct; 34(10):1359-1366. PubMed ID: 28718080
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
16. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
17. Thirteen years' experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments.
Creux H; Monnier P; Son WY; Buckett W
J Assist Reprod Genet; 2018 Apr; 35(4):583-592. PubMed ID: 29502188
[TBL] [Abstract][Full Text] [Related]
18. Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study.
Zhao F; Lan Y; Chen T; Xin Z; Liang Y; Li Y; Wang S; Zhang J; Yang X
J Ovarian Res; 2020 Feb; 13(1):23. PubMed ID: 32113477
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
20. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
